Close Menu

Marina Biotech said this week that it has priced an underwritten public offering of 6.375 million units of stock and warrants at $0.80 each, for total gross proceeds of $5.1 million.

Each unit, Marina said, consists of one share of common stock and 0.1746 of a warrant to buy one share of common stock. The warrants are exercisable immediately and have a seven-year term.

The offering is expected to close mid-February, the company added.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.

Vox writes that lab mishaps involving pathogens are quite common.

In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.

Apr
17
Sponsored by
Isoplexis

This webinar will provide an overview of current biomarker strategies for guiding the use of combination checkpoint immunotherapies in blood cancers.